Skip to main content
  • Home
  •  Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Roundtable Discussion

Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Roundtable Discussion

Topic:
  • Prevention

Available Credit:

  • Not accredited

Course Published On:

Course Expiry Date:

No ratings

Overview

This roundtable is designed to provide clinicians with a better understanding of the long-term CV risks of LDL-C exposure. In addition to reviewing the pathogenesis of atherosclerosis and assessing the long-term implications of elevated LDL-C, this meeting will consider current guidance around controlling LDL-C, the challenges in achieving LDL-C targets, and evaluating how emerging strategies are contributing to LDL-C management. 

 

Each chapter will comprise of a short presentation by the named medical expert followed by a panel discussion amongst all faculty.  

Target Audience

  • Healthcare Professionals
  • General Cardiologists

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Outline the pathogenic nature and clinical risk of extended exposure to elevated LDL-C
  • Describe the clinical challenges in achieving guidance-based LDL-C goals
  • Compare and contrast LDL-C lowering therapies
This course is not accredited

Related Courses

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
CVD and Type 2 Diabetes: Navigating Therapeutic Boundaries in GLP-1 RA Use
  • 2.00 EBAC

Learning objectives

  • Describe the burden of ASCVD in type 2 diabetes
  • Assign risk of future CV events to individuals with type 2 diabetes
  • Identify appropriate patients for GLP-1 RA therapy based on clinical trial outcome data to reduce ASCVD risk
  • Recall trial data of anti-diabetes medications that reduce ASCVD risk
  • Recall the pleiotropic effects of GLP-1 RAs and how these may impact CV outcomes
  • Describe how early adoption of anti-diabetes therapies with proven CV benefit can positively influence QOL
  • Adopt anti-diabetic therapies with proven ASCVD benefit
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more